Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Alzheimer's Disease Neuroimaging Initiative 2 (ADNI2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01231971
Recruitment Status : Completed
First Posted : November 1, 2010
Last Update Posted : January 21, 2020
Sponsor:
Collaborators:
Northern California Institute of Research and Education
National Institute on Aging (NIA)
Alzheimer's Therapeutic Research Institute
Information provided by (Responsible Party):
Paul Aisen, University of Southern California

Brief Summary:
The purpose of this study is to build upon the information obtained in the original Alzheimer's Disease Neuroimaging Initiative (ADNI1) and ADNI-GO (Grand Opportunity; a study funded through an NIH grant under the American Recovery and Reinvestment Act), to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). ADNI2 seeks to inform the neuroscience of AD. This information will aid in the early detection of AD, and in measuring the effectiveness of treatments in future clinical trials.

Condition or disease Intervention/treatment
Mild Cognitive Impairment (MCI) Alzheimer's Disease (AD) Significant Memory Concern (SMC) Early Mild Cognitive Impairment (EMCI) Late Mild Cognitive Impairment (LMCI) Drug: Florbetapir Drug: Flortaucipir

Detailed Description:

The Alzheimer's Disease Neuroimaging Initiative (ADNI) began in October 2004 as a landmark study with a public-private partnership that gathered and analyzed thousands of brain scans, genetic profiles and biomarkers in blood and cerebrospinal fluid (CSF). Although the original goal was to define biomarkers for use in clinical trials to determine the best way to measure treatment effects of Alzheimer's disease (AD), the goal has been expanded to using biomarkers to identify AD at a pre-dementia stage. ADNI1 involves scientists at 59 research centers, 54 in the U.S. and five in Canada. Originally 800 participants were enrolled. This group was comprised of 200 participants with AD, 400 with mild cognitive impairment (MCI) and 200 with normal cognition. In ADNI-GO, an estimated 200 participants with early amnestic MCI (EMCI) were enrolled to understand and characterize the mildest symptomatic phase of AD. An additional 650 participants will be enrolled under ADNI2.

Some of the leading-edge technologies under study are brain-imaging techniques, such as positron emission tomography (PET), including FDG-PET (which measures glucose metabolism in the brain); PET using a radioactive compound (Florbetapir F 18) that measures brain beta-amyloid; and structural MRI. Brain scans are showing scientists how the brain's structure and function change as AD starts and progresses. Biomarkers in cerebrospinal fluid are revealing other changes that could identify which patients with MCI will develop Alzheimer's. Scientists are looking at levels of beta-amyloid and tau in cerebrospinal fluid. (Abnormal amounts of the amyloid and tau proteins in the brain are hallmarks of Alzheimer's disease.)

ADNI2 extends the work of ADNI1 and ADNI GO to understand the progression of AD. The overall goal is to determine the relationships among the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of AD, as the pathology evolves from normal aging through very mild symptoms, to MCI, to dementia.

The overall impact of this study will be increased knowledge concerning the sequence and timing of events leading to MCI and AD, development of better clinical and imaging/fluid biomarker methods for early detection and for monitoring the progression of these conditions, and facilitation of clinical trials to slow disease progression, ultimately contributing to the prevention of AD.

Layout table for study information
Study Type : Observational
Actual Enrollment : 1182 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Alzheimer's Disease Neuroimaging Initiative 2
Study Start Date : January 2011
Actual Primary Completion Date : September 28, 2017
Actual Study Completion Date : November 29, 2017

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Cognitively Normal (CN)
150 newly enrolled participants with no apparent memory problems, and CN participants followed from the ADNI1 study
Drug: Florbetapir
Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) (+/- 10%) florbetapir F18. At approximately 50-minutes post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.
Other Name: 18F-AV-45, LY3078786

Drug: Flortaucipir
Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) flortaucipir injection followed by a saline flush. At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
Other Name: 18F-AV-1451 (also known as [F-18]T807 or LY3191748)

Early Mild Cognitive Impairment (EMCI)
100 newly enrolled early amnestic MCI participants, and approximately 200 EMCI participants will be followed from the ADNI-GO study
Drug: Florbetapir
Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) (+/- 10%) florbetapir F18. At approximately 50-minutes post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.
Other Name: 18F-AV-45, LY3078786

Drug: Flortaucipir
Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) flortaucipir injection followed by a saline flush. At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
Other Name: 18F-AV-1451 (also known as [F-18]T807 or LY3191748)

Late Mild Cognitive Impairment (LMCI)
150 newly enrolled late MCI participants, and LMCI participants followed from the ADNI1 study
Drug: Florbetapir
Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) (+/- 10%) florbetapir F18. At approximately 50-minutes post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.
Other Name: 18F-AV-45, LY3078786

Drug: Flortaucipir
Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) flortaucipir injection followed by a saline flush. At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
Other Name: 18F-AV-1451 (also known as [F-18]T807 or LY3191748)

Alzheimer's Disease (AD)
150 newly enrolled mild AD participants
Drug: Florbetapir
Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) (+/- 10%) florbetapir F18. At approximately 50-minutes post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.
Other Name: 18F-AV-45, LY3078786

Drug: Flortaucipir
Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) flortaucipir injection followed by a saline flush. At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
Other Name: 18F-AV-1451 (also known as [F-18]T807 or LY3191748)

Significant Memory Concern (SMC)
100 newly enrolled participants with Significant Memory Concern (SMC)
Drug: Florbetapir
Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) (+/- 10%) florbetapir F18. At approximately 50-minutes post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.
Other Name: 18F-AV-45, LY3078786

Drug: Flortaucipir
Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) flortaucipir injection followed by a saline flush. At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
Other Name: 18F-AV-1451 (also known as [F-18]T807 or LY3191748)




Primary Outcome Measures :
  1. Rate of volume change of whole brain, hippocampus and other structural MRI measures [ Time Frame: 5 Years ]

Secondary Outcome Measures :
  1. Rate of Decline as measured by: Cognitive Tests, Activities of Daily Living, and CDR Sum of Boxes [ Time Frame: 5 Years ]
  2. Rate of conversion will be evaluated among all five groups [ Time Frame: 5 Years ]
  3. Rates of change on each specified biochemical biomarker [ Time Frame: 5 Years ]
  4. Rates of change of glucose metabolism (FDG-PET) [ Time Frame: 5 Years ]
  5. Extent of amyloid deposition as measured by Florbetapir F 18 [ Time Frame: 4 Years ]
  6. Group differences for each imaging and biomarker measurement [ Time Frame: 5 Years ]
  7. Correlations among biomarkers and biomarker change [ Time Frame: 4 Years ]
  8. APOE genotype, low CSF Aβ42, positive amyloid imaging with florbetapir F 18 (AV-45) [ Time Frame: 5 Years ]
  9. Rate of change of tau and extent of tau deposition as measured by flortaucipir (18F-AV-1451) [ Time Frame: 1 Year ]
  10. Rate of cognitive decline using computer based testing as measured by Cogstate Brief Battery (CBB) [ Time Frame: 1 year ]

Biospecimen Retention:   Samples With DNA
blood, urine, cerebrospinal fluid


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   55 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Community Sample
Criteria

Inclusion Criteria:

Participants will be classified as either normal controls, SMC, EMCI, LMCI or AD participants. General Inclusion Criteria will apply to all groups, with specific criteria for each group as described below:

General (applies to each category):

  • Geriatric Depression Scale less than 6.
  • Age between *55-90 (inclusive). *For normal controls and SMC participants, age must be between 65-90.
  • Study partner is available who has frequent contact with the participant (e.g. an average of 10 hours per week or more), and can accompany the participant to all clinic visits for the duration of the protocol.
  • Visual and auditory acuity adequate for neuropsychological testing.
  • Good general health with no diseases expected to interfere with the study.
  • Participant is not pregnant, lactating, or of childbearing potential (i.e. women must be two years post-menopausal or surgically sterile).
  • Willing and able to participate in a longitudinal imaging study.
  • Hachinski less than or equal to 4.
  • Completed six grades of education or has a good work history (sufficient to exclude mental retardation).
  • Must speak English or Spanish fluently.
  • Willing to undergo repeated MRIs (3Tesla) and at least two PET scans (one FDG and one Amyloid imaging) and no medical contraindications to MRI.
  • Agrees to collection of blood for Genome Wide Association Studies (GWAS), APOE testing and DNA and RNA banking.
  • Agrees to collection of blood for biomarker testing.
  • Agrees to at least one lumbar puncture for the collection of CSF.

Specific Inclusion Criteria for normal controls:

  • Participant must be free of memory complaints, verified by a study partner.
  • Normal memory function score on Wechsler Memory Scale (adjusted for education)
  • Mini-Mental State Exam (MMSE) score between 24 and 30 (inclusive)
  • Clinical Dementia Rating (CDR) = 0; Memory Box score must be 0
  • Cognitively normal, based on an absence of significant impairment in cognitive functions or activities of daily living
  • Stability of Permitted Medications for 4 weeks. In particular, participants may take:

    • Antidepressants lacking significant anticholinergic side effects
    • Estrogen replacement therapy is permissible
    • Gingko biloba is permissible, but discouraged
    • Washout from psychoactive medication (e.g., excluded antidepressants, neuroleptics, chronic anxiolytics or sedative hypnotics, etc.) for at least 4 weeks prior to screening

Specific Inclusion Criteria for SMC participants:

  • Subjects that are "self-referrals" that have a significant subjective memory concern
  • Significant memory concern confirmed by a Cognitive Change Index score of more than or equal to 16
  • Normal memory function score on Wechsler Memory Scale (adjusted for education)
  • Mini-Mental State Exam (MMSE) score between 24 and 30 (inclusive)
  • Clinical Dementia Rating (CDR) = 0; Memory Box score must be 0
  • Cognitively normal, based on the absence of significant memory impairment in cognitive function or activities of daily living
  • Stability of Permitted Medications for 4 weeks. In particular, subjects may take:

    • Antidepressants lacking significant anticholinergic side effects
    • Estrogen replacement therapy is permissible
    • Gingko biloba is permissible, but discouraged
    • Washout from psychoactive medication (e.g., excluded antidepressants, neuroleptics, chronic anxiolytics or sedative hypnotics, etc.) for at least 4 weeks prior to screening

Specific Inclusion Criteria for EMCI and LMCI participants:

  • Participant must have a subjective memory concern as reported by participant, study partner, or clinician
  • Abnormal memory function score on Wechsler Memory Scale (adjusted for education)
  • Mini-Mental State Exam (MMSE) score between 24 and 30 (inclusive)
  • Clinical Dementia Rating (CDR) = 0.5; Memory Box score must be at least 0.5
  • General cognition and functional performance sufficiently preserved such that a diagnosis of AD cannot be made by the site physician at the time of the screening visit
  • Stability of Permitted Medications for 4 weeks. In particular, participants may take:

    • Antidepressants lacking significant anticholinergic side effects
    • Estrogen replacement therapy
    • Gingko biloba is permissible, but discouraged
    • Washout from psychoactive medication (e.g., excluded antidepressants, neuroleptics, chronic anxiolytics or sedative hypnotics, etc.) for at least 4 weeks prior to screening
    • Cholinesterase inhibitors and memantine are allowable if stable for 12 weeks prior to screening

Specific Inclusion Criteria for AD participants:

  • Participant must have a subjective memory concern as reported by participant, study partner, or clinician
  • Abnormal memory function score on Wechsler Memory Scale (adjusted for education)
  • Mini-Mental State Exam (MMSE) score between 20 and 26 (inclusive)
  • Clinical Dementia Rating (CDR) = 0.5 or 1.0
  • National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for probable AD
  • Stability of Permitted Medications for 4 weeks. In particular, participants may take:

    • Antidepressants lacking significant anticholinergic side effects
    • Estrogen replacement therapy
    • Gingko biloba is permissible, but discouraged
    • Washout from psychoactive medication (e.g., excluded antidepressants, neuroleptics, chronic anxiolytics or sedative hypnotics, etc.) for at least 4 weeks prior to screening
    • Cholinesterase inhibitors and memantine are allowable if stable for 12 weeks prior to screening

Specific Inclusion Criteria for follow-up participants from ADNI1 and ADNI GO:

  • Must have been enrolled and followed in ADNI1 for at least one year or enrolled in ADNI-GO with original diagnosis of Cognitively Normal (CN), Mild Cognitive Impairment (MCI), or Early Mild Cognitive Impairment (EMCI) regardless of whether a diagnostic conversion has occurred since initial enrollment in ADNI.
  • Willing and able to continue to participate in an ongoing longitudinal study. A reduced battery of tests is allowable if the participant is not able/willing to complete the full battery.
  • Study partner is available who has frequent contact with the participant (e.g. an average of 10 hours per week or more), and can accompany the participant to all clinic visits for the duration of the protocol.

Exclusion Criteria:

General (applies to each category):

  • Screening/baseline MRI scan with evidence of infection, infarction, or other focal lesions; Participants with multiple lacunes or lacunes in a critical memory structure are excluded
  • Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body
  • Major depression, bipolar disorder as described in Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) within the past 1 year
  • Currently treated with medication for obsessive-compulsive disorder or attention deficit disorder
  • History of schizophrenia
  • History of alcohol or substance abuse or dependence within the past 2 years
  • Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol
  • Clinically significant abnormalities in B12, or TFTs that might interfere with the study
  • Residence in skilled nursing facility
  • Current use of specific psychoactive medications (e.g.,certain antidepressants, neuroleptics, chronic anxiolytics or sedative hypnotics, etc.); Current use of warfarin or dabigatran (exclusionary for lumbar puncture).
  • Use of investigational agents one month prior to entry and for the duration of the trial
  • Participation in clinical studies involving neuropsychological measures being collected more than one time per year
  • Exclusion for FDG PET scan and amyloid imaging with Florbetapir F 18: Current or recent participation in any procedures involving radioactive agents such that the total radiation dose exposure to the participant in any given year would exceed the limits of annual and total dose commitment set forth in the US Code of Federal Regulations (CFR) Title 21 Section 361.1.
  • Exceptions to these guidelines may be considered on a case-by-case basis at the discretion of the protocol director

Specific Exclusion Criteria for normal controls and SMC participants:

  • Any significant neurologic disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities

Specific Exclusion Criteria for EMCI and LMCI participants:

  • Any significant neurologic disease other than suspected incipient Alzheimer's disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities.

Specific Exclusion Criteria for AD participants:

  • Any significant neurologic disease other than Alzheimer's disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities.

Specific Exclusion Criteria for follow-up participants from ADNI1 and ADNI GO:

  • Participants will not be able to participate in FDG PET scan and amyloid imaging with Florbetapir F 18 if the following is true: Current or recent participation in any procedures involving radioactive agents such that the total radiation dose exposure to the participant in any given year would exceed the limits of annual and total dose commitment set forth in the US Code of Federal Regulations (CFR) Title 21 Section 361.1.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01231971


Locations
Show Show 58 study locations
Sponsors and Collaborators
University of Southern California
Northern California Institute of Research and Education
National Institute on Aging (NIA)
Alzheimer's Therapeutic Research Institute
Investigators
Layout table for investigator information
Principal Investigator: Ronald Petersen, MD, PhD Mayo Clinic
Principal Investigator: Michael W. Weiner, MD University of California, San Francisco
Principal Investigator: Paul S. Aisen, MD University of Southern California
Additional Information:
Publications:
Layout table for additonal information
Responsible Party: Paul Aisen, Professor, University of Southern California
ClinicalTrials.gov Identifier: NCT01231971    
Other Study ID Numbers: ADC-039-ADNI2
U01AG024904 ( U.S. NIH Grant/Contract )
First Posted: November 1, 2010    Key Record Dates
Last Update Posted: January 21, 2020
Last Verified: January 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Paul Aisen, University of Southern California:
amyloid
plaques
neuroimaging
biomarkers
cognition disorder
early detection
Amnestic MCI
pre-dementia
dementia
Alzheimer's disease
tau
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Cognitive Dysfunction
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cognition Disorders